SCHEMBL14570945

SCHEMBL14570945

CC1CC(C)Oc2cc3c(cc2O1)-c1n[nH]c(Nc2ccc(F)c(Cl)c2)c1C3C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 5/20 0.41
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPKAPK2 P49137 4/20 0.33
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
HPGD P15428 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
APP P05067 1/20 0.32
CDK2 P24941 2/20 0.32
ROCK2 O75116 1/20 0.32
MAPK9 P45984 1/20 0.32
GSK3B P49841 1/20 0.32
MAP2K1 Q02750 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14571151 0.87 SGK1 (0.32) AURKBMEN1KMT2A
SCHEMBL14571148 0.85 FADS1 (0.33) GRM4LMNAALOX15RAPGEF4MAPT
SCHEMBL14571081 0.81 EGFR (0.34) RAPGEF4MAP2K1
SCHEMBL4043198 0.81 EGFR (0.45) GRM4ALDH1A1LMNATDO2AURKA
SCHEMBL4050643 0.78 GRM4 (0.41) GRM4ALDH1A1LMNAALOX15SMN1; SMN2
SCHEMBL4043851 0.78 FBP1 (0.48) GRM4LMNAAURKAAURKB
SCHEMBL4048321 0.66 EGFR (0.40) ALDH1A1LMNAALOX15SMN1; SMN2POLB
SCHEMBL4046364 0.66 PDGFRB (0.48) ALDH1A1LMNAALOX15SMN1; SMN2HPGD
SCHEMBL4041829 0.64 FADS1 (0.42) GRM4LMNAALOX15SMN1; SMN2RAPGEF4
SCHEMBL4044573 0.64 EGFR (0.44) ALDH1A1LMNAAURKBPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed